HUTCHMED (China) Limited Sponsored ADR

HCM Healthcare Drug Manufacturers Specialty & Generic

HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.

14.27 0.35 +2.51%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
3.53
Beneish M
−1.20
Dividend safety
n/a
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.64 4.96 4.65 2.83
Net Debt/EBITDA
0.00 0.00 0.00 0.00
Debt/Equity
0.07 0.07 0.08 0.11
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 0.00 0.00
Free Cash Flow
6.60 (78.78) (82.15) (17.44)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates